View abstract

This abstract is assigned to session BOG-SBO: Chirurgisch netvlies / Retine chirurgicale

Title	The use of microplasmin in vitreoretinal surgery: a phase II clinical trial
Abstract Nr.	184

Purpose	Enzymatic induction of a posterior vitreous detachment may be beneficial in enhancing vitrectomy for vitreomacular interface disorders. At present, only autologous plasmin is known to be a relative safe drug for this purpose. However, isolation of this enzyme is a tedious process and is not standardized. Microplasmin is a recombinant enzyme derived from human plasmin. The aim of this phase II multi-centric study is to evaluate the clinical use and possible side-effects of microplasmin injected intravitreally before vitrectomy.
Methods	60 patients will be included with vitreomacular traction (idiopathic or diabetic) or macular hole (stages II or III). The drug is injected in variable dosage and at different time intervals before the surgery (6 cohorts). Clinical results and possible side-effects are evaluated before the surgery and up to 6 months after the surgery using ophthalmic examination, funduscopy, angiography, electrophysiology and OCT.
Results	At present, 16 patients are included in the study. No serious side effects related to the injected microplasmin have been reported.

Author 1

Last name	STALMANS
Initials	P
Department	UZLeuven
City	Leuven

Author 2

Last name	Feron
Initials	E
Department	Eye Hospital Rotterdam
City	Rotterdam, The Netherlands

Author 3

Last name	Gandorfer
Initials	A
Department	Dept of Ophthalmology, Ludwig Maximilians University
City	Munich, Germany

Author 4

Last name	Kampik
Initials	A
Department	Dept of Ophthalmology, Ludwig Maximilians University
City	Munich, Germany

Author 5

Last name	De Smet
Initials	MD
Department	Academic Medical Center
City	Amsterdam, The Netherlands